A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874
This study is recruiting at 11 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Colon Cancer
- Pancreatic Cancer
- Lung Cancer (NSCLC)
- Advanced Cancer
- Advanced Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Pheon Therapeutics
- Last updated on ClinicalTrials.gov
- September 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- PHN-012-001 Site · Los Angeles, CA
- PHN-012-001 Site · San Diego, CA
District of Columbia · 1
- PHN-012-001 Site · Washington D.C., DC
Massachusetts · 1
- PHN-012-001 Site · Boston, MA
Missouri · 1
- PHN-012-001 Site · St Louis, MO
North Carolina · 1
- PHN-012-001 Site · Durham, NC
Oregon · 1
- PHN-012-001 Site · Portland, OR
Tennessee · 1
- PHN-012-001 Site · Nashville, TN
Texas · 2
- PHN-012-001 Site · Houston, TX
- PHN-012-001 Site · San Antonio, TX
Virginia · 1
- PHN-012-001 Site · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.